Tailoring Treatment Approaches in Psoriasis Management - Episode 3

Incorporating Clinical Guidelines in Psoriasis Management

Published on: March 27, 2025

Jason Hawkes, MD, MS, Saakshi Khattri, MD, James Song, MD, Fabrizio Galimberti, MD, PhD

Panelists discuss how biologic therapies for psoriasis are increasingly considered earlier in treatment algorithms based on the American Academy of Dermatology-National Psoriasis Foundation (AAD-NPF) Guidelines and updated International Psoriasis Council (IPC) severity classifications, with decisions influenced by disease extent, impact on quality of life, presence of psoriatic arthritis, treatment history, patient preferences, and the recognition that prompt intervention with biologics can prevent disease progression and comorbidities in patients with moderate to severe disease.

EP. 1: Challenges in Defining Psoriasis Severity in Clinical Practice

EP. 2: Clinical Considerations for Assessing Plaque Psoriasis Severity and Identifying Psoriatic Arthritis

Now Viewing

EP. 3: Incorporating Clinical Guidelines in Psoriasis Management

EP. 4: Navigating Biologic Treatment Selection in Psoriasis and Psoriatic Arthritis

EP. 5: Exploring Undertreatment of Psoriasis in Skin of Color

EP. 6: Advancing From Topicals to Systemic Treatment in Psoriasis Management

Video content above is prompted by the following:

Current treatment guidelines (AAD-NPF Guidelines) recommend biologic therapies for the management of moderate to severe psoriasis. When do you consider biologics for your patients?
IPC updated severity classification